The statement below if pretty important, wait until investors get a load of the fact that Rafarma already has deals in place with pharma giants Pfizer, Abbot Labs and probably others to make generic versions of their medications....they are going to be all over this.
What particular advantages does this trend provide for Rafarma? As the population of elderly citizens throughout Eastern Europe has grown, so too has economic turmoil stressed the affordability and accessibility of necessary drugs. Russian government mandates requiring physicians use Rafarma products combined with the lower price of generic pharmaceuticals proffers companies such as Rafarma a unique niche within the Eastern European Pharmaceuticals market: Growing demand and a struggling economy equate to increased favorability, from both healthcare providers and individuals, towards companies that provide cheaper products.